Gilead Sciences, Inc. $GILD Shares Purchased by NewEdge Advisors LLC

NewEdge Advisors LLC boosted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 12.7% in the 2nd quarter, Holdings Channel reports. The firm owned 442,389 shares of the biopharmaceutical company’s stock after purchasing an additional 49,954 shares during the period. NewEdge Advisors LLC’s holdings in Gilead Sciences were worth $55,891,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the fourth quarter worth $25,000. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at $25,000. Kimelman & Baird LLC purchased a new stake in shares of Gilead Sciences in the 2nd quarter valued at $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Finally, Quattro Advisors LLC acquired a new position in Gilead Sciences during the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on GILD shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $155.00 target price on shares of Gilead Sciences in a research report on Wednesday, August 5th. Needham & Company LLC reissued a “buy” rating and set a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Wall Street Zen lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Saturday. Weiss Ratings cut shares of Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Finally, Daiwa Securities Group dropped their price objective on shares of Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a report on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $158.04.

Gilead Sciences Trading Down 2.9%

GILD opened at $146.64 on Wednesday. Gilead Sciences, Inc. has a 12 month low of $108.46 and a 12 month high of $157.29. The stock has a market capitalization of $181.83 billion, a price-to-earnings ratio of -54.92 and a beta of 0.33. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The business has a fifty day moving average price of $137.57 and a 200 day moving average price of $136.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.Gilead Sciences’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.01 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th will be issued a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is -122.85%.

Insider Transactions at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares in the company, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the transaction, the chief financial officer owned 165,646 shares of the company’s stock, valued at $22,918,780.56. This trade represents a 1.78% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 105,000 shares of company stock valued at $14,495,820 over the last quarter. Insiders own 0.30% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company’s research focuses primarily on virology, oncology, inflammation and related areas, with products serving patients in the United States and international markets.

Gilead is best known for its HIV treatments, including Biktarvy, Genvoya, Descovy and other antiretroviral therapies. Its portfolio also includes medicines for viral hepatitis, such as Epclusa and Vemlidy, and Veklury (remdesivir), an antiviral treatment for COVID-19.